

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



李 氏 大 藥 廠

Lee's Pharmaceutical Holdings Limited

李 氏 大 藥 廠 控 股 有 限 公 司 *

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 950)

VOLUNTARY ANNOUNCEMENT – UPDATE ON THE INTRODUCTION AND RESEARCH AND DEVELOPMENT OF AN INVESTIGATIONAL ONCOLOGY PRODUCT

This announcement is made by the board of directors (the “Board”) of Lee’s Pharmaceutical Holdings Limited (the “Company”, together with its subsidiaries as the “Group”) on a voluntary basis.

The Board of the Company is pleased to announce that, on 27 September 2018, the first patient has been enrolled in China in the Phase 1 clinical trial for Anti-PD-L1 monoclonal antibody, ZKAB001, on cervical cancer, and the first dosing has been administered on 10 October 2018.

The trial will be conducted by two centers, Cancer Hospital Chinese Academy of Medical Sciences and Wuhan Union Hospital with Doctor Lingying Wu as the principal investigator. The trial consists of two phases, a traditional open labeled 3+3 dose escalation phase followed by an expansion phase. In the dose escalation phase, 3 doses, 5, 10, 15 mg/kg, will be tested with 14 days administration cycle in patients with recurrent and metastatic cervical cancer. Once the maximum tolerated dose (“MTD”) has been determined, 60 patients will be enrolled under MTD treatment as an expansion phase.

There are over 100,000 new cases of cervical cancer in China every year. The recurrent rate after the first line treatment is high. There is an urgent medical needs to have a new standard second line treatment in China and around the world. With the rapid development of immune checkpoint inhibitor, anti-PD-L1 antibody, ZKAB001, can become a new hope to the patients in need.

ZKAB001 is a fully human anti-PD-L1 monoclonal antibody (mAb), an immune checkpoint inhibitor. The mAb blocks the interaction of PD-L1 protein with its receptor PD-1, then suppressing the inhibition of PD-1/PDL1 signal to T cells and enhancing the killing effect of T cells on tumors. This antibody also kills cancer cells through traditional antibody-dependent cell-mediated cytotoxicity (“ADCC”). It was licensed from Sorrento Therapeutics, Inc. (SRNE) to China Oncology Focus Limited, a 65% owned subsidiary of the Group, in fourth quarter of 2014.

The Group is fully integrated with solid infrastructures in drug development, clinic, perspectives and currently markets 17 products in the PRC. The Group focuses on several different areas such as cardiovascular and infectious diseases, dermatology, oncology, gynecology, ophthalmology and others. It has more than 50 products under different development stages stemming from both internal R&D as well as from the recent acquisition of licensing and distribution rights from various US, European and Japanese companies.

By order of the Board
Lee’s Pharmaceutical Holdings Limited
Lee Siu Fong
Chairman

Hong Kong, 10 October 2018

* *For identification purpose only*

As at the date of this announcement, Ms. Lee Siu Fong (Chairman), Ms. Leelalertsuphakun Wanee and Dr. Li Xiaoyi are executive directors of the Company, Mr. Simon Miles Ball is a non-executive director of the Company, Dr. Chan Yau Ching, Bob, Mr. Lam Yat Cheong and Dr. Tsim Wah Keung, Karl are independent non-executive directors of the Company.